Member Info for Jatw

Seems v low coverage or activity.....would be nice to have a second opinion near berenbergs 1400p

FY results due on 12 March.
Looking for indications that NB is picking up and more clarity on the capital generation plan.

Seems unlikely there will be a business update ahead of the results (probably a good thing).
SP still sensitive to interest rates, Boris bounce helping the sp

It will have to be jam tomorrow for GSK. They are some way behind the revitalisation at AZN which despite an initial 5% fall on disappointing results has managed to recover most of that fall unlike GSK that has fallen back and not risen.

Will consider buying more is 12-18months time. The drug pipeline and demerger prospects should be clearer.

Thank you falklandinvestor....you have to bank the gain at some point. We have been fortunate that Many of the life assurers have bounced back from their crisis lows to new highs.....LGEN and PRU in particular. I Have been taking profits in Pru for the last few years to diversify.

Slightly disappointing increase in value....but Savo milestones to be added later in the year....
May need some more cash early 2021.

What is the collective wisdom of contributors to this discussion board

Would you like to share your reasoning as you were suggesting 375-400 as a selling price.
You do t have to but this is what these boards are for..

I am holding till atleast after the results which I expect will be strong.

Not an expert, but my reading is that there is evidence of positive disease management in ORR and PFS.
The treatment is applicable across all types of bio markers tested, the 40% ORR for MET must be not statistically meaningful due to small numbers.
Encouraging...but further work to do.

Results: 42 patients were enrolled with 41 receiving at least one dose of study treatment. Safety and efficacy analyses were performed on these 41 patients. The median follow up was 14.3 months. IMDC good, intermediate and poor risk disease occurred in 29%, 63%, and 7% of patients respectively. Overall confirmed RR was 27% while median PFS was 4.9 months (95% CI: 2.5 – 12.0 months). Median OS was 12.3 months (95% CI: 5.8 – 21.3 months). Confirmed RR and median OS in the previously untreated cohort (N=27) were 33% and 12.3 months (95% CI: 4.7 – not reached (NR) months) respectively. Treatment related Grade 3/4 toxicity occurred in 34% of patients. No new safety signals were seen. PD-L1 and MET expression were not associated with higher RR (25% and 40% respectively) or longer OS. Conclusions: The combination of savolitinib and durvalumab has clinical activity in PRC and outcomes were not enhanced in biomarker positive cancers. Clinical trial information: NCT02819596. Research Sponsor: AstraZeneca.

5% off seems a bit of an over reaction....buy the dip

Generally agree a4003075....but not sure it is China... there is not a single reference to China in the trading update nor a China office..so I don’t know that China is particularly relevant....it certainly has not hit other pharma related stocks.

Maybe the results will be early....

Taking this in its stride. Going nicely stateside, 435p equivalent.

Buy the dips when they happen.

Surprisingly stable today. I have not seen the alleged broker note.....but why would they produce this between the trading update and the accounts with much more information available is beyond me. The risk of looking a fool is quite large unless they have been briefed (insider info).

What is the concern?
Too much DA?
Too much debt?

https://uk.finance.yahoo.com/news/focus-coronavirus-outbreak-begins-disrupt-172724671.html

As flagged possible disruption.....atleast the NDAs for Suru are in the bag

If this were bad news they would need to tell the market of a failed trial.....hence it must be ok or good news.

After the initial shock of the placing, the market seems to have digested the issue pretty well and has been on a steady rise for 2 weeks.....
Buy any significant dips caused by external events as this will be largely noise over positive fundamentals.

Thanks both.
P19 of the corporate presentation references the opportunity in. 2bn$ market and says important data update planned.....
Savo alone
and imfinzi + Savo (Orr better than keytruda at the last outing)

An indicator of importance will be whether they hold an update call (as SANET-ep) or leave it to comment in the FY reporting.

This completes the first column of newsflow in the company presentation p8. Three gold star events expected soon.

Generically, Boards perceive that the market applies a conglomerate discount to their individual businesses.
In many businesses there will be competing units for finite capital, hence some may be run for cash and others for the future receiving the investment. The market starts to devalue the cash unit because it it not investing enough.......and the growth promised by the unit given the investment is delayed.....the result is the parent is devalued.....it then thinks the market could reprice both units if they were separated thus creating (revealing previously hidden) value.
There is a history of companies breaking themselves up.....some go well, in many cases the smaller units are taken over within a short time.
Hanson industries
ICI (Zeneca now part of AZN)
Most recent example is Prudential where MNG was demerged.

Ghost RNS can’t be read and is missing from HCM website
Imfinzi + Savo phase 2 interim. Must be coming soon